Texaphyrins are members of the �expanded porphyrin� class ofmacrocycles. They are able to coordinate larger metal cations and have beenexplored as experimental therapeutic agents. Motexafin gadolinium (MGd), aspecific gadolinium(III) texaphyrin (Gd-Tex) complex, has been the subject ofseveral clinical trials; it is well tolerated and localizes to solid tumors. FDA-approved Pt(II)-based drugs are mainstays in cancerchemotherapy. However, they are not well tolerated. Further, tumor resistance isgenerally seen following initial treatment responses. An approach to increasingthe therapeutic index by both overcoming this resistance, and reducing systemictoxicity would be to develop Pt complexes that target cancerous lesions. Tothis effect, we have created several Gd-Tex-Pt conjugates. These systems havebeen synthesized with the goal of improving the to-tumor delivery of active Ptspecies and reducing the toxicity see for cisplatin and other non-specific Ptbased therapeutics. Herein, we report a summary of efforts to date.

Recent advances in the biomedical applications of texaphyrins

239th National Meeting (2010)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.